10x Genomics (NASDAQ:TXG) Given Sell (D-) Rating at Weiss Ratings

Key Points

• 10x Genomics has been given a "sell (D-)" rating by Weiss Ratings, indicating negative outlook from the ratings agency.
• The company reported a quarterly earnings per share of $0.28, significantly beating analysts' expectations of a loss, while revenue increased by 12.9% year-over-year.
• Several major firms have varied opinions on the stock, with price targets ranging from $12.00 to $15.00 and a current consensus rating of "Hold."

10x Genomics (NASDAQ:TXG - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Tuesday,Weiss Ratings reports.

Several other research firms also recently commented on TXG. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the stock a "hold" rating in a research note on Friday, August 8th. Bank of America lifted their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Thursday, June 26th. Barclays reaffirmed an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. UBS Group boosted their price objective on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Finally, Morgan Stanley dropped their price target on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $13.65.

10x Genomics Trading Down 1.2%

Shares of TXG stock traded down $0.14 on Tuesday, reaching $11.46. 483,239 shares of the company's stock were exchanged, compared to its average volume of 3,239,969. The company's fifty day simple moving average is $12.94 and its 200 day simple moving average is $11.09. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $18.21. The stock has a market capitalization of $1.43 billion, a PE ratio of -16.36 and a beta of 2.05.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business had revenue of $172.91 million during the quarter, compared to analyst estimates of $139.36 million. During the same period in the previous year, the company posted ($0.32) EPS. 10x Genomics's revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, sell-side analysts predict that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In other news, CEO Serge Saxonov sold 9,348 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the sale, the chief executive officer directly owned 945,892 shares in the company, valued at $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the sale, the insider directly owned 440,888 shares of the company's stock, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 39,149 shares of company stock worth $539,865. 10.03% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its position in 10x Genomics by 1,487.5% in the 1st quarter. GAMMA Investing LLC now owns 31,306 shares of the company's stock valued at $273,000 after purchasing an additional 29,334 shares during the last quarter. Rhumbline Advisers raised its stake in shares of 10x Genomics by 11.4% during the first quarter. Rhumbline Advisers now owns 120,490 shares of the company's stock valued at $1,052,000 after purchasing an additional 12,374 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of 10x Genomics by 12.8% during the first quarter. SG Americas Securities LLC now owns 82,406 shares of the company's stock valued at $719,000 after purchasing an additional 9,360 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in 10x Genomics by 9.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 31,061 shares of the company's stock worth $271,000 after purchasing an additional 2,564 shares in the last quarter. Finally, Diversified Trust Co raised its holdings in shares of 10x Genomics by 60.8% in the 1st quarter. Diversified Trust Co now owns 57,236 shares of the company's stock worth $500,000 after purchasing an additional 21,634 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.